Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Shionogi, Galderma Boost Acne Patients Educational Campaign
July 19, 2010
- Multiple Companies to Launch Generics of Pariet
July 19, 2010
- GW, Otsuka to Extend Cannabinoid Research Collaboration for 3 Years
July 19, 2010
- Banyu Invite 200 Employees to Early Retirement Program
July 19, 2010
- Nichi-Iko to Promote Generic of Amaryl with sanofi-aventis' Support
July 19, 2010
- Linagliptin Effective for Controlling Blood Glucose both in Mono-, Combination Therapy
July 19, 2010
- Maruishi Aims at Sales of ¥50.0 Bil. in Mid Term
July 19, 2010
- Teva-Kowa Aims at Sales of ¥20.0 Bil. in 2010
July 19, 2010
- JZOLOFT Found Non-Inferior to Paxil: Pfizer Japan
July 19, 2010
- Over 50% of Major Drug Makers Hire Fewer New Graduates
July 19, 2010
- High Sales Cost Major Problem for Generics Business in Japan
July 19, 2010
- PMDA to Identify Challenges for Prior Assessment System
July 19, 2010
- Ethical Drugs' Sales Remain Flat in May: Crecon Report
July 19, 2010
- Nippon Shinyaku to Start Clinical Trials for RNA Drugs in FY2013
July 19, 2010
- Procedures Changed for Applications Based on Data from Public Domain
July 19, 2010
- Rezaltas Remains No. 1 in HP Market
July 19, 2010
- 6 Firms to Receive Subsidies to Enhance New-Type Flu Vaccines Production Capacity
July 19, 2010
- JPMA Asks Member Companies Not to Talk about New Drug Development Premium
July 19, 2010
- Daiichi Sankyo to Integrate Ranbaxy's NDDR
July 19, 2010
- Pfizer's ALK Inhibitor to Be Launched in 2012: Dr Wagner of Kantar Health
July 19, 2010
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…